ACAAI 2020 Allied Health Professionals Course

November 14, 2020 to November 15, 2020

The Changing Practice Landscape

Rising to the Challenge

Target Audience

Health professionals including, but not limited to, RNs, LPNs, MAs, PAs, NPs, MDs/DOs.

Learning Objectives

At the conclusion of this activity, participants should be able to:

  • Identify major advances in key areas of cutting edge research in immunologic mechanisms and allergic responses, including anaphylaxis and pathophysiology of the upper airways, lungs, eyes, skin and gastrointestinal tract
  • Demonstrate knowledge of basic processes linking molecular and cellular biology and genetics with allergic pathophysiology and immunodeficiency
  • Translate emerging clinical science principles to clinical practice in patients with allergic and immunologic diseases
  • Evaluate and implement state-of-the-art diagnostic and therapeutic strategies for treating patients with allergic and immunologic diseases
  • Explain the impact of environmental exposures and external influences on patients with allergic disorders
  • Recognize emerging trends in the prevalence of allergic and immunologic disorders and discuss their impact on public health
  • Evaluate the impact of new diagnostic and therapeutic strategies on health care costs and outcomes
  • Discuss processes, tools and technologies for the efficient allergy and immunology practice
Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewers, and other individuals in a position to control or influence the content of an activity must disclose all relevant financial relationships with any commercial interest that have occurred within the past 12 months. All identified conflicts of interest must be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity. Individuals with no relevant financial relationships must also inform the learners that no relevant financial relationships exist. Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials. Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI.

All identified conflicts of interest have been resolved.

 

Course summary
Available credit: 
  • 6.75 AANP
  • 6.75 AMA PRA Category 1 Credit™
  • 6.75 Attendance
Course opens: 
11/14/2020
Course expires: 
11/13/2023
Event starts: 
11/14/2020 - 3:00pm CST
Event ends: 
11/15/2020 - 4:30pm CST
Moscone West Convention Center
San Francisco, CA
United States

Available Credit

  • 6.75 AANP
  • 6.75 AMA PRA Category 1 Credit™
  • 6.75 Attendance
Please login or create an account to take this course.